

## REMARKS

Claims 19-20 and 22-36 are pending in this application. Claims 1-18, 21, and 37-46 were previously cancelled. Claim 19 has been amended to include the phrase “wherein the buffer comprises a substrate for nitric oxide synthetase,” support for which may be found throughout the specification, notably at page 5, lines 19-20. Upon entry of these amendments, claims 19-20 and 22-36 are under active consideration. Applicant respectfully requests entry of the amendment and remarks made herein into the file history of the present application.

### **1. The rejection under 35 U.S.C. § 103 over Virag should be withdrawn.**

The Examiner has rejected claims 19-20 and 22-36 under 35 U.S.C. § 103 as obvious over Virag. The Examiner characterizes Virag as teaching a composition of papaverine, phentolamine, and alprostadil.

Applicant has amended claim 19 to include the phrase “wherein the buffer comprises a substrate for nitric oxide synthetase.” Therefore, Applicant respectfully traverses the rejection on the basis of Virag because Virag does not teach or suggest a method of administering a composition comprising an  $\alpha$ -adrenergic blocker and a prostaglandin in a buffer, *wherein the buffer comprises a substrate for nitric oxide synthetase*. Because the cited reference does not teach or suggest each and every limitation of the claims as amended, Applicant respectfully requests the Examiner withdraw the rejection under 35 U.S.C. § 103.

### **2. A Terminal Disclaimer under 37 C.F.R. 1.321 (c) is filed herewith in response to the nonstatutory obviousness-type double patenting rejection.**

Claims 19-20 and 22-36 were rejected under the judicially created doctrine of obviousness-type double patenting as allegedly being unpatentable over claims 18-37 of U.S. Patent No. 6,482,426. Applicants file a terminal disclaimer herewith.


### 3. Conclusion

In view of the above amendments and remarks, and the terminal disclaimer filed herewith, Applicant respectfully submits that the instant application is in good and proper order for allowance and early notification to this effect is solicited. If, in the opinion of the Examiner, a telephone conference would expedite prosecution of the instant application, the Examiner is encouraged to call the undersigned at the number listed below.

Respectfully submitted,

HOWREY SIMON ARNOLD & WHITE, LLP

Dated: January 26, 2005

By:   
Teddy C. Scott, Jr., Ph.D.  
Registration No.: 53,573  
Customer No.: 22930

HOWREY SIMON ARNOLD & WHITE, LLP  
321 N. Clark Street, Suite 3400  
Chicago, IL 60661  
(312) 595-1239 (main)  
(312) 846-5621 (direct)  
(312) 595-2250 (fax)